DMKPQ (DMK Pharmaceuticals) Interest Expense: $-0.08 Mil (TTM As of Sep. 2023)


DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Interest Expense?

DMK Pharmaceuticals DMKPQ -99.00% 16 Interest Expense is $-0.08 Mil as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. DMK Pharmaceuticals's interest expense for the three months ended in Sep. 2023 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.08 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. DMK Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $ -3.27 Mil. DMK Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $ -0.03 Mil. DMK Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

DMK Pharmaceuticals  (OTCPK:DMKPQ) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

DMK Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $-0.03 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-3.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.

DMK Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

DMK Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

DMK Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Interest Expense Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -0.12 -0.01 -0.01 0.00

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.05 -0.03
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.08 Mil mean?
DMK Pharmaceuticals (DMKPQ) has a Interest Expense of $-0.08 Mil as of Sep. 2023. Interest Expense is the amount a company pays on its long-term debt. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Interest Expense too high?
DMK Pharmaceuticals' current Interest Expense is $-0.08 Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Interest Expense compare to CNNC and THCT?
DMK Pharmaceuticals' Interest Expense of $-0.08 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Interest Expense is $-0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Interest Expense of $-0.08 Mil. The current Interest Expense is $-0.08 Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Interest Expense is $-0.08 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price